Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Lokhorst HM, et al. Among authors: wijermans p. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Haematologica. 2008. PMID: 18166796 Free article. Clinical Trial.
Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW. Lokhorst HM, et al. Among authors: wijermans pw. Br J Haematol. 1996 Jan;92(1):44-8. doi: 10.1046/j.1365-2141.1996.00306.x. Br J Haematol. 1996. PMID: 8562409 Clinical Trial.
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Löwenberg B, et al. Among authors: wijermans p. Blood. 1997 Oct 15;90(8):2952-61. Blood. 1997. PMID: 9376575 Free article. Clinical Trial.
[Multiple myeloma; treatment in the year 1998].
Lokhorst HM, Sonneveld P, Wijermans PW, Segeren CM. Lokhorst HM, et al. Among authors: wijermans pw. Ned Tijdschr Geneeskd. 1998 Jul 11;142(28):1596-602. Ned Tijdschr Geneeskd. 1998. PMID: 9763840 Review. Dutch.
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW. Lokhorst HM, et al. Among authors: wijermans pw. Bone Marrow Transplant. 1999 Feb;23(4):317-22. doi: 10.1038/sj.bmt.1701574. Bone Marrow Transplant. 1999. PMID: 10100574 Clinical Trial.
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Segeren CM, et al. Among authors: wijermans pw. Br J Haematol. 1999 Apr;105(1):127-30. Br J Haematol. 1999. PMID: 10233375 Free article. Clinical Trial.
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P, Wijermans PW, van der Lelie J, van Putten WL, Löwenberg B. Ossenkoppele GJ, et al. Among authors: wijermans pw. Leukemia. 1999 Aug;13(8):1207-13. doi: 10.1038/sj.leu.2401478. Leukemia. 1999. PMID: 10450748 Clinical Trial.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group. Segeren CM, et al. Among authors: wijermans pw. Blood. 2003 Mar 15;101(6):2144-51. doi: 10.1182/blood-2002-03-0889. Epub 2002 Nov 27. Blood. 2003. PMID: 12456509 Free article. Clinical Trial.
Early response to therapy and survival in multiple myeloma.
Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Schaar CG, et al. Among authors: wijermans pw. Br J Haematol. 2004 Apr;125(2):162-6. doi: 10.1111/j.1365-2141.2004.04884.x. Br J Haematol. 2004. PMID: 15059138 Free article. Clinical Trial.
206 results